Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alectinib - Roche

Next Previous
Search
Drug Profile

Alectinib - Roche

Alternative Names: AF-802; Alecensa; ALECENSARO; Alectinib hydrochloride; CH-5424802; RG-7853; RO-5424802; RO-5452802

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche
  • Class Antineoplastics; Carbazoles; Morpholines; Nitriles; Phenyl ethers; Piperidines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer; Anaplastic large cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic large cell lymphoma; Non-small cell lung cancer
  • Phase II Solid tumours
  • Phase I/II Brain cancer; Thyroid cancer

Most Recent Events

  • 28 Apr 2025 Chugai Pharmaceutical completes the phase III ALEX trial for Non-Small Cell Lung Cancer (Metastatic disease, Recurrent, Late-stage disease, First line therapy) in USA, Australia, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Costa Rica, France, Guatemala, Greece, Egypt, Hong Kong, Israel, Italy, South Korea, Mexico, New Zealand, Poland, Portugal, Russia, Serbia, Spain, Singapore, Switzerland, Thailand, Taiwan, Turkey, Ukraine, United Kingdom (PO) (NCT02075840)
  • 02 Oct 2024 Roche plans a phase II HORIZON 2 trial for Non-small cell lung cancer (Late-stage disease, neoadjuvant therapy, combination therapy) in Chile (PO) (NCT06624059)
  • 07 Sep 2024 Updated adverse events data from the phase III ALINA trial in ALK-positive Non-small cell lung cancer presented at the 25th World Conference on Lung Cancer (WCLC-2024)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top